Neurocrine Biosciences price to free cash flow NBIX
Market value divided by free cash flow over the last twelve months, since 2018.
- Today, Nov 2, 2026
- 17.0×
- 8-year median
- 35.5×
- Against its 8-year history
- 2nd
- percentile: 0 is its lowest day, 100 its highest
- 8-year range
- 15.8× to 214×
- Peer median
- 25.2×
Neurocrine Biosciences' price to free cash flow is 17.0× as of Nov 2, 2026.
That is below its 8-year median of 35.5×, lower than on 98% of days in the last 8 years.
Over that time it ranged from 15.8× in Oct 2026 to 214× in Nov 2019.
The median for 10 biotech stocks of a similar size is 25.2×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 17.0× | 15.8× | 23.7× |
| 2025 | 24.4× | 16.3× | 34.9× |
| 2024 | 32.1× | 22.0× | 38.9× |
| 2023 | 33.7× | 27.4× | 66.8× |
| 2022 | 64.9× | 22.1× | 92.8× |
| 2021 | 25.1× | 23.5× | 49.3× |
| 2020 | 38.4× | 25.6× | 126× |
| 2019 | 122× | 91.2× | 214× |
| 2018 | 88.3× | 88.3× | 136× |
Against its peers
Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| NBIXNeurocrine Biosciences | 17.0× |
| HALOHalozyme Therapeutics | 18.2× |
| EXELExelixis | 14.8× |
| TECHBIO-TECHNE | 43.3× |
| ALNYAlnylam Pharmaceuticals | 26.7× |
| RGENRepligen | 87.2× |
| INCYIncyte | 12.7× |
| KRYSKrystal Biotech | 34.0× |
| UTHRUnited Therapeutics | 23.7× |
| ONCBeOne Medicines | 30.2× |
| ADMAAdma Biologics | 21.3× |
| Peer median | 25.2× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Neurocrine Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.